Uncooled TATO microwave system for liver ablation.

IF 1.2 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2022-12-01 DOI:10.2217/hep-2022-0002

Eduardo Crespo, Antonio Hermosín, Álvaro Villalba, Eduardo Daguer, José Flores, Javier Periañez, Mario Martínez-Galdámez, Ernesto Santos

引用次数: 0

Abstract

Aim: To evaluate the safety and efficacy of uncooled TATO microwave ablation (MWA) for primary and metastatic liver cancer.

Materials & methods: This was a retrospective study on percutaneous liver ablations performed with TATO MWA. Twenty-five ablations were performed; 11 (44%) were performed for hepatocellular carcinoma, 14 (56%) for colorectal carcinoma, gastric and pancreatic metastases.

Results: Adverse events were reported only in one (4%) ablation: an abscess that was observed in the ablated area and was resolved with a percutaneous drainage and antibiotic therapy. Local tumor control rate was 92% at the 3-month follow-up.

Conclusion: TATO MWA was safe and effective with high reproducibility in treating primary and secondary liver cancer with satisfactory technical and clinical outcomes.

Abstract Image

查看原文本刊更多论文

用于肝脏消融的非冷却式TATO微波系统。

目的:评价非冷却马铃薯微波消融治疗原发性和转移性肝癌的安全性和有效性。材料与方法:这是一项采用TATO MWA进行经皮肝消融的回顾性研究。消融25例;11例(44%)为肝细胞癌，14例(56%)为结直肠癌、胃和胰腺转移。结果:不良事件仅在一例(4%)消融中报告:在消融区域观察到脓肿，经皮引流和抗生素治疗得以解决。随访3个月，局部肿瘤控制率为92%。结论:TATO MWA治疗原发性和继发性肝癌安全有效，重复性高，技术和临床效果满意。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.